AI in clinical trials: faster recruits, smarter designs, growing trust

Artificial intelligence has edged past the pilot phase in clinical development. Once a niche add-on, AI is now helping biopharma companies design, recruit, and run trials faster, cheaper, and—crucially—more inclusively. And regulators are starting to pay serious attention.

From trial start-up to endpoint submission, AI-driven tools are reshaping how the industry approaches clinical evidence. Whether it’s mining electronic health records, simulating digital patients, or flagging anomalies in real time, sponsors are seeing measurable gains. But long-term regulatory acceptance remains a work in progress.